News | April 14, 2014

World’s First Pacemaker Series With Event-Triggered IEGM Transmissions Gains CE Mark

New Biotronik pacemaker series offers daily automatic data transmission without relying on patient interaction

April 14, 2014 — Biotronik recently announced CE approval for its new Eluna pacemaker series. The new generation of pacemakers includes single- and dual-chamber as well as cardiac resynchronization (CRT-P) devices.

With unique event-triggered IEGM (intracardiac electrogram) transmissions, the new Biotronik pacemaker series innovates advanced patient monitoring and allows physicians to receive an IEGM along with a notification if atrial fibrillation (AF) occurs. By notifying physicians of clinical events quickly and reliably, patient therapy can be adapted at the earliest stage possible, preventing the worsening of a patient’s condition and the occurrence of secondary diseases. Since nearly 25 percent of pacemaker patients suffer from AF, a type of atrial tachyarrhythmia that can be difficult to detect due to its silent nature, continuous and reliable monitoring is crucial. Biotronik Home Monitoring is said to have the most reliable data transmission rates yet.

“The new Biotronik pacemaker series is truly a step forward in terms of reliability and patient security,” said Hendrik Bonnemeier, M.D., of the University Clinic Schleswig-Holstein, Kiel, Germany. “Its unique ability to transmit automatic, event-triggered IEGMs really helps me deliver the best therapy, letting me know immediately if something happens to the device or patient post-implantation. The sooner I know, the sooner I can react and that may save my patient’s life.”

CRT-P Devices Offer Crucial Improvements in Heart Failure Treatment

Numerous studies have shown that devices with Biotronik Home Monitoring aid patient therapy and significantly improve quality of life by reducing instances of hospitalization and stroke. In the IN-TIME study, the solution was shown to reduce mortality in heart failure patients by more than 50 percent, making Biotronik CRT devices especially important in effective heart failure therapy.

Additionally, the new device family features ProMRI full-body scan in the single and dual-chamber pacemakers, and ProMRI capability in the CRT-P devices, enabling patients to undergo crucial MRI (magnetic resonance imaging) scans on nearly every part of the body.

“If the goal of a pacemaker is to help the patient live life to the fullest, almost to the point where he forgets he has a pacemaker, then the new Biotronik pacemaker series truly succeeds,” said Daniel Gras, M.D., of the New Clinic Nantes, France. “It is also truly astonishing how far ProMRI technology has come in recent years. Now that there is no longer an exclusion zone, I can diagnose any kind of comorbidity.”

“With the development of our new pacemaker series, we have once again demonstrated our commitment to excellence for life,” commented Christoph Böhmer, president international at Biotronik. “Now that remote monitoring and MR conditional devices are highly recommended in the ESC [European Society of Cardiology] guidelines, we are proud to say that our new pacemaker series reflects reliable and innovative care that follows these guidelines, with a longevity that is truly the best on the market.”

For more information: www.biotronik.com

Related Content

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init